Mueller Shane R, Koester Stephen, Glanz Jason M, Gardner Edward M, Binswanger Ingrid A
Institute for Health Research, Kaiser Permanente Colorado, 10065 E. Harvard Ave., Suite 300, Denver, CO, 80231, USA.
Department of Health and Behavioral Sciences, University of Colorado Denver, Denver, CO, USA.
J Gen Intern Med. 2017 Mar;32(3):277-283. doi: 10.1007/s11606-016-3895-8. Epub 2016 Oct 31.
Over the last 2 decades, medical providers have increasingly prescribed pharmaceutical opioids for chronic non-cancer pain, while opioid overdose death rates have quadrupled. Naloxone, an opioid antagonist, can be prescribed to patients with chronic pain to reverse an opioid overdose, yet little is known about how patients perceive this emerging practice.
This study assessed the knowledge and attitudes toward naloxone prescribing among non-cancer patients prescribed opioids in primary care.
Qualitative study design using semi-structured interviews.
Adults (N = 24) prescribed high-dose (≥100 morphine mg equivalent daily dose) chronic opioid therapy in eight primary care internal medicine, family medicine and HIV practices in three large Colorado health systems.
Inductive and deductive methods were used to analyze interview transcripts.
Themes emerged related to knowledge of and benefits, barriers and facilitators to naloxone in primary care. Patients reported receiving limited education about opioid medication risks from providers and limited knowledge of naloxone. When provided with a description of naloxone, patients recognized its ability to reverse overdoses. In addition to pragmatic barriers, such as medication cost, barriers to naloxone acceptance included the perception that overdose risk stems from medication misuse and that providers might infer that they were misusing their opioid medication if they accepted a naloxone prescription, prompting an opioid taper. Facilitators to the acceptance of naloxone included medical providers' using empowering, non-judgmental communication practices, framing naloxone for use in "worst case scenarios" and providing education and training about opioids and naloxone.
While patients recognized the utility of naloxone prescribing, we identified important barriers to patient acceptance of naloxone prescribing. To improve the naloxone prescribing acceptability in primary care practice, medical providers and health systems may need to enhance patient education, employ empowering, non-judgmental communication styles and adequately frame discussions about naloxone to address patients' fears.
在过去20年中,医疗服务提供者越来越多地为慢性非癌性疼痛开具阿片类药物,而阿片类药物过量死亡率翻了两番。纳洛酮是一种阿片类拮抗剂,可以开给慢性疼痛患者以逆转阿片类药物过量,但对于患者如何看待这种新做法知之甚少。
本研究评估了在初级保健中开具阿片类药物的非癌症患者对纳洛酮处方的知识和态度。
采用半结构化访谈的定性研究设计。
在科罗拉多州三个大型医疗系统的八个初级保健内科、家庭医学和艾滋病毒诊所中,接受高剂量(≥100毫克吗啡当量每日剂量)慢性阿片类药物治疗的成年人(N = 24)。
采用归纳和演绎方法分析访谈记录。
出现了与初级保健中纳洛酮的知识、益处、障碍和促进因素相关的主题。患者报告称,从医疗服务提供者那里获得的关于阿片类药物风险的教育有限,对纳洛酮的了解也有限。当向患者描述纳洛酮时,他们认识到其逆转过量用药的能力。除了药物成本等实际障碍外,纳洛酮接受度的障碍还包括认为过量风险源于药物滥用,以及如果接受纳洛酮处方,医疗服务提供者可能会推断他们在滥用阿片类药物,从而促使减少阿片类药物用量。纳洛酮接受度的促进因素包括医疗服务提供者采用增强信心、无偏见的沟通方式,将纳洛酮用于“最坏情况”的框架设定,以及提供关于阿片类药物和纳洛酮的教育与培训。
虽然患者认识到纳洛酮处方的效用,但我们发现了患者接受纳洛酮处方的重要障碍。为了提高初级保健实践中纳洛酮处方的可接受性,医疗服务提供者和医疗系统可能需要加强患者教育,采用增强信心、无偏见的沟通方式,并充分构建关于纳洛酮的讨论,以消除患者的恐惧。